HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) wit

BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or t

Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analys

To our valued Shareholders,As we progress through 2026 and look ahead to delivering continued signif

BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) wit

Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S.,

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S.,

BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or

MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treat

BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or t

Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment o

BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or

Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analys

BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or

Gain Therapeutics (NASDAQ: GANX) is developing oral small-molecule drugs aimed at neurodegenerative

BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage

Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD

Gain Therapeutics, Inc. (NASDAQ: GANX - Get Free Report) shot up 3.7% on Monday. The stock traded as

Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints,

BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or

BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or

Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage b

BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or

Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) wit

BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or

Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage b

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph)

Does Gain Therapeutics, Inc. (GANX) have what it takes to be a top stock pick for momentum investors

Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.15) per share which beat the analys

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) wit

Maxim Group analyst Jason McCarthy maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and raise

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continui

Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an addi

BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $

Roth Capital analyst Boobalan Pachaiyappan maintains Gain Therapeutics (NASDAQ:GANX) with a Buy a

U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesd